Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Arrowhead Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 33.4% ve 39.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 36.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -2283.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

33.4%

Kazanç büyüme oranı

36.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	34.5%
Gelir büyüme oranı	39.5%
Gelecekteki özkaynak getirisi	-2,283.7%
Analist kapsamı	Good
Son güncelleme	24 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0HI3 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2027	351	-302	-348	-154	9
9/30/2026	195	-468	-389	-311	12
9/30/2025	276	-309	268	285	16
9/30/2024	4	-599	-604	-463	N/A
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	152	157	N/A
3/31/2019	95	10	130	132	N/A
12/31/2018	47	-29	134	136	N/A
9/30/2018	16	-54	-49	-47	N/A
6/30/2018	14	-54	N/A	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A
9/30/2014	0	-59	N/A	-35	N/A
6/30/2014	0	-50	N/A	-30	N/A
3/31/2014	0	-44	N/A	-25	N/A
12/31/2013	0	-37	N/A	-22	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0HI3 şirketinin gelirinin (yıllık 39.5% ) UK pazarından (yıllık 3.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0HI3 şirketinin gelirinin (yıllık 39.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0HI3 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/25 00:26
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/09/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Arrowhead Pharmaceuticals, Inc. 29 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Ying Huang	Barclays
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Recent updates

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

CEO, President & Director recently sold US$567k worth of stock

Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity

New minor risk - Revenue size

Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023)

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 23% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 27% overvalued after recent price rise

First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023)

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

New major risk - Financial position

New major risk - Financial position

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022)

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Chief Medical Officer recently sold US$567k worth of stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Insider selling

Chief Financial Officer recently sold US$543k worth of stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022)

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Independent Director recently sold US$291k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chairman of the Board recently sold US$326k worth of stock

Chief Commercial Officer James Hassard has left the company

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020)

Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Chief Commercial Officer recently sold US$323k worth of stock